ES2051740T3 - Un procedimiento para la formacion de pequeñas vesiculas unilaminares que encapsulan un antibiotico polienico. - Google Patents

Un procedimiento para la formacion de pequeñas vesiculas unilaminares que encapsulan un antibiotico polienico.

Info

Publication number
ES2051740T3
ES2051740T3 ES87307221T ES87307221T ES2051740T3 ES 2051740 T3 ES2051740 T3 ES 2051740T3 ES 87307221 T ES87307221 T ES 87307221T ES 87307221 T ES87307221 T ES 87307221T ES 2051740 T3 ES2051740 T3 ES 2051740T3
Authority
ES
Spain
Prior art keywords
vesicles
antibiotic
polyenic
encapsulate
laminated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87307221T
Other languages
English (en)
Inventor
Jill Adler-Moore
Ronald Carl Gamble
Richard Thomas Proffitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vestar Inc filed Critical Vestar Inc
Application granted granted Critical
Publication of ES2051740T3 publication Critical patent/ES2051740T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN FORMULACIONES QUE CONSISTEN EN PARTICULAS UNILAMELARES PEQUEÑAS DE FOSFOLIPIDOS QUE ENCAPSULAN ANTIBIOTICOS ANTIFUNGICOS POLIENICOS Y METODOS PARA USAR DICHAS COMPOSICIONES PARA TRATAR INFECCIONES DE HONGOS SISTEMICAS. LAS PARTICULAS ESTAN EN FORMA DE VESICULAS QUE COMPRENDEN UN ANTIBIOTICO ANTIFUNGICO POLIENICO, PREFERIBLEMENTE ANFOTERICINA B Y/O NISTATINA, FOSFATIDILCOLINA DE HUEVO Y COLESTEREOL, PREFERIBLEMENTE EN LA RELACION MOLAR DE 2(AMB):2(PL):1(CHOL). ESTA VESICULAS TAMBIEN PUEDEN TENER UNA SUPERFICIE AMINA MODIFICADA. LAS VESICULAS ESTAN SUSPENDIDAS EN UNA SOLUCION DE SACARIDOS/TRIS DE ESCASA FUERZA IONICA A UN PH DE 6,0 A 8,0 Y PUEDEN SER ADMINISTRADAS PARA PORPORCIONAR EL ANTIBIOTICO ANTIFUNGICO EN EL TRATAMIENTO DE INFECCIONES DE HONGOS SISTEMICAS.
ES87307221T 1986-08-21 1987-08-14 Un procedimiento para la formacion de pequeñas vesiculas unilaminares que encapsulan un antibiotico polienico. Expired - Lifetime ES2051740T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89906486A 1986-08-21 1986-08-21

Publications (1)

Publication Number Publication Date
ES2051740T3 true ES2051740T3 (es) 1994-07-01

Family

ID=25410437

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87307221T Expired - Lifetime ES2051740T3 (es) 1986-08-21 1987-08-14 Un procedimiento para la formacion de pequeñas vesiculas unilaminares que encapsulan un antibiotico polienico.

Country Status (14)

Country Link
US (1) US5874104A (es)
EP (1) EP0260811B1 (es)
JP (1) JPH0615475B2 (es)
KR (1) KR950013747B1 (es)
AT (1) ATE66597T1 (es)
AU (1) AU606880B2 (es)
CA (1) CA1292184C (es)
DE (1) DE3772498D1 (es)
DK (1) DK168982B1 (es)
ES (1) ES2051740T3 (es)
GR (1) GR3002852T3 (es)
HK (1) HK115393A (es)
IE (1) IE60901B1 (es)
NO (1) NO174833C (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2620028B2 (fr) * 1986-12-05 1994-02-25 Ire Celltarg Sa Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US4812312A (en) * 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US4999199A (en) * 1988-11-10 1991-03-12 Board Of Regents, The University Of Texas System Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
JP2653245B2 (ja) * 1989-11-27 1997-09-17 日本新薬株式会社 脂肪乳剤
JPH06509058A (ja) * 1991-01-14 1994-10-13 ボード、オブ、リージェンツ、ザ、ユニバーシティー、オブ、テキサス、システム リポソームニスタチン及びアンホテリシンbの抗hiv活性
WO1993007884A1 (en) * 1991-10-25 1993-04-29 Senju Pharmaceutical Co., Ltd. External preparation for treating hemorrhoidal diseases
JP2915296B2 (ja) * 1993-08-30 1999-07-05 宇野 潤 抗真菌製剤
GB9519654D0 (en) * 1995-09-27 1995-11-29 Nycomed Imaging As Stabilised phospholipid compositions
KR100505772B1 (ko) 1996-01-25 2005-10-25 쉐링 악티엔게젤샤프트 개선된정맥투여용농축주사액및주입액
GB9721901D0 (en) * 1997-10-16 1997-12-17 Univ Manchester Particles
AU1350099A (en) * 1997-12-01 1999-06-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulations for topical treatment of skin infections
IT1301807B1 (it) * 1998-06-25 2000-07-07 Tiberio Bruzzese Formulazioni farmaceutiche iniettabili di derivati della partricina.
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
JP4786041B2 (ja) * 2001-03-02 2011-10-05 丸善製薬株式会社 渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス, インコーポレイテッド タンパク様薬剤およびその使用
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
EP1981525B1 (en) 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Extended release of neuregulin for improved cardiac function
AU2008287340A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
NZ596778A (en) 2009-06-08 2013-11-29 Amunix Operating Inc Glucose-regulating polypeptides and methods of making and using same
CN106916229A (zh) 2009-06-08 2017-07-04 阿穆尼克斯运营公司 生长激素多肽及其制备和使用方法
CA3027255C (en) 2009-07-10 2022-06-21 The General Hospital Corporation Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
RU2481100C2 (ru) * 2009-10-16 2013-05-10 Лайфкеа Инновейшнз Пвт. Лтд. Новая лекарственная форма для лечения грибковой инфекции
BR112012009801A8 (pt) 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
ES2677352T3 (es) 2009-12-18 2018-08-01 Achelios Therapeutics, Inc. Métodos y composiciones para tratar y prevenir las cefaleas autonómicas trigeminales, la migraña y las afecciones vasculares
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
EP2668961A4 (en) * 2010-11-19 2016-07-06 Univ Sapporo Medical PHARMACEUTICAL COMBINATION PREPARATION
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
WO2013184938A2 (en) 2012-06-08 2013-12-12 Alkermes. Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CN107124869B (zh) 2014-03-25 2022-04-01 美国政府陆军部 包含含有单磷酰脂质a(mpla)的脂质体组合物和皂苷的无毒佐剂制剂
US20170266106A1 (en) 2014-12-01 2017-09-21 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
JP6833811B2 (ja) 2015-08-03 2021-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 荷電イオンチャネル遮断薬及び使用方法
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ix融合蛋白以及其製備及使用方法
KR20180077180A (ko) 2015-11-06 2018-07-06 아쥬반스 테크놀로지스 인코포레이티드 트리테르펜 사포닌 유사체
CN110023321A (zh) 2016-08-17 2019-07-16 索尔斯蒂斯生物有限公司 多核苷酸构建体
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
SG11202001826YA (en) 2017-10-16 2020-03-30 Adjuvance Technologies Inc Triterpene saponin analogues
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病aを処置する方法
CA3129089A1 (en) 2019-03-11 2020-09-17 Bridget Mccarthy Cole Ester substituted ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
AU2020237474A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US20220307013A1 (en) 2019-08-30 2022-09-29 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
KR20220123381A (ko) 2019-11-06 2022-09-06 녹시온 테라퓨틱스 인코포레이티드 하전된 이온 채널 차단제 및 사용 방법
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP4118070A4 (en) 2020-03-11 2024-04-10 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
WO2023175454A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. Methods for producing an adjuvant
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310505A (en) * 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4497791A (en) * 1983-02-10 1985-02-05 Vestar Research Incorporated Method for labeling phagocytic cells
GB2135647A (en) * 1983-02-15 1984-09-05 Squibb & Sons Inc Method of preparing liposomes and products produced thereby
PT78628B (en) * 1984-05-02 1986-06-18 Liposome Co Inc Pharmaceutical composition with reduced toxicity
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
CA1298548C (en) * 1984-10-22 1992-04-07 Cary Arnet Presant Method of delivering micellular particles encapsulating imaging and chemotherapeutic agents to tumors in a body
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4766046A (en) * 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
US4812312A (en) * 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin

Also Published As

Publication number Publication date
NO873492D0 (no) 1987-08-19
NO873492L (no) 1988-02-22
KR950013747B1 (ko) 1995-11-15
EP0260811A3 (en) 1988-07-20
EP0260811A2 (en) 1988-03-23
KR880002531A (ko) 1988-05-09
ATE66597T1 (de) 1991-09-15
DK434187D0 (da) 1987-08-20
DE3772498D1 (de) 1991-10-02
NO174833B (no) 1994-04-11
AU606880B2 (en) 1991-02-21
EP0260811B1 (en) 1991-08-28
US5874104A (en) 1999-02-23
CA1292184C (en) 1991-11-19
JPH0615475B2 (ja) 1994-03-02
GR3002852T3 (en) 1993-01-25
HK115393A (en) 1993-11-05
JPS6366123A (ja) 1988-03-24
NO174833C (no) 1994-07-20
AU7716087A (en) 1988-02-25
DK434187A (da) 1988-02-22
IE872148L (en) 1988-02-21
DK168982B1 (da) 1994-07-25
IE60901B1 (en) 1994-08-24

Similar Documents

Publication Publication Date Title
ES2051740T3 (es) Un procedimiento para la formacion de pequeñas vesiculas unilaminares que encapsulan un antibiotico polienico.
AU587232B2 (en) Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
DE3855265D1 (de) Liposomen-Formulierungen mit hohem antineoplastischem Wirkstoff/Lipid-Verhältnis
GR1000074B (el) Λιποειδη σφαιριδια (κυστιδια) για ενδοπεριτονειακη χορηγηση θεραπευτικων παραγοντων.
EP0340592A3 (de) Haarbehandlungsmittel mit natürlichen Inhaltsstoffen
FI971776A (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
DK0542864T3 (da) Anvendelse af phospholipider til fremstilling af et topisk lægemiddel til modifikation af serumcholesterolniveauer
EP0361936A3 (en) Lasing compositions and methods for using the same
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
DK32388D0 (da) Phospholipid-baeremiddel for vand-uoploeselige aktive bestanddele
IT8720800A0 (it) Composto attivo nella terapia carciovascolare.
BR6600785U (pt) Brinquedo eletronico-video-game para jogos e passatempos
IT1214693B (it) Fosfati loro preparazione e loro impiego come agenti ingnifuganti
SE8604669D0 (sv) Medel for behandling av svampinfektioner i naglar